FDA will expedite review of cancer drug Istodax for expanded use

02/28/2011 | Reuters

The FDA granted priority-review status to Celgene's Istodax for use in patients with peripheral T-cell lymphoma who have undergone prior treatment. The agency, which approved the drug for cutaneous T-cell lymphoma, is expected to decide by June 17 on the expanded use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC